Tiziana Life Sciences announced a publication in the preeminent1 journal, Proceedings of the National Academy of Sciences, that illustrates the immunological basis of the mechanism of action (MoA) for intranasal foralumab. "This upcoming quarter will be an eventful and productive period for Tiziana," stated Matthew W. Davis, M.D., RPh, Chief Medical Officer of Tiziana. "The publication of foralumab’s detailed mechanism of action dovetails with our forthcoming Alzheimer’s IND filing for intranasal foralumab and the Phase 2 FDA review comments for our proposed MS trial, all of which are expected this month. March will also be the third month of intranasal foralumab administration in four Expanded Access patients followed by data updates in Q2 2023.Tiziana remains on track to begin its Phase 2 intranasal foralumab non-active Secondary Progressive Multiple Sclerosis trial in Q3 of this year."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly